This follow-up trial for those subjects in a randomized, double-blind, phase 2/3 trial of monotherapy vs. combination therapy with nucleoside analogues in HIV-infected persons with CD4 cells <=200 or >=500 mm3 provides the opportunity to carefully characterize subjects who have a well-defined nucleoside analog exposure history with respect to their symptomatic state, their CD4 trajectory, and their virologic profile, and to relate this to the response to new antiretroviral interventions.
Showing the most recent 10 out of 642 publications